Doctor Pharmacy

Brand Name:

Sust M ‘250’

10mL/Vial

(Testosterone Propionate)
(Testosterone Phenylpropionate)
(Testosterone Isocaproate)
(Testosterone Decanoate)

Manufactured By:

Munster Laboratories Switzerland

Composition:

Each ml of the oily solution contains:

testosterone propionate (Eur. P.)………… 30 mg

testosterone phenylpropionate (B.P.)……. 60 mg

testosterone isocaproate (B.P.)…………... 60 mg

testosterone decanoate (B.P.)……………100 mg

Characteristics:

Sust M ‘250’ is an androgenic preparation for intramuscular administration containing four different esters of the natural hormone testosterone. Testosterone propionate has a rapid onset and a short duration of action. Testosterone phenylpropionate and isocaproate have a less rapid onset and a long duration of action. By combining these testosterone esters, the action of Sustanon ‘250’ starts shortly after injection and is maintained for about three weeks.

Sust M ‘250’ is generally well tolerated and has no adverse effect on the liver.

Indications:

Testosterone replacement therapy in male hypogonadal disorders, for example:
-    after castration
-    eunuchoidism
-    hypopituitarism
-    endocrine impotence
-    male climacteric symptoms such as decreased libido and decreased mental and physical activity
-    certain types of infertility due to disorders of spermatogenesis;
Moreover, testosterone therapy may be indicated in osteoporosis due to androgen deficiency.
 
Dosage:

In general, dosage should be adjusted according to the response of the individual patient. Usually, one injection of 1 ml per three weeks is adequate or as prescribed by the physician.

Administration:

Sust M ‘250’ should be administered by deep intramuscular injection.

Contra-indications:

-    Known or suspected prostatic or mammary carcinoma.

Warnings and precautions:

-    If androgen associated adverse reactions occur, treatment should be interrupted and after disappearance of the symptoms, should be resumed at a lower dosage.

-    Patients with latent or overt cardiac failure, renal dysfunction, hypertension, epilepsy or migraine (or a history of these conditions) should be monitored, since androgens may occasionally induce salt and fluid retention.

-    Androgens should be used cautiously in prepubertal boys to avoid premature epiphyseal closure or precocious sexual development.

-    Oligosperma and decreased ejaculatory volume.
-    A decrease in protein-bound iodine (PBI) may occur, but this has no clinical significance.

Adverse reactions:

The following adverse reactions have been associated with androgen therapy:
-    Priapism and other signs of excessive sexual stimulation.

-    In prepubertal boys, precocious sexual development, an increased frequency of erections, phallic enlargement and premature epiphyseal closure.

-    Water and salt retention.
-    Oligosperma and decreased ejaculatory volume.

Instructions:

To be sold on the prescription of a registered medical practitioner only.

Store at 8-30°C. Protect from light.

Keep out of the reach of children.